Obicetrapib for Antioxidant Deficiency

(VERMEER Trial)

This trial explores whether Obicetrapib, a new potential drug, can boost antioxidant levels in the blood and eye tissues. Antioxidants protect cells from damage. Participants will take either Obicetrapib or a placebo daily for four months, with clinic visits every eight weeks for checkups and tests. The trial suits individuals with clear vision (better than 20/60 with or without glasses) and no major eye problems, but not those with type 2 diabetes or liver disease. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Obicetrapib has been tested in people to assess its safety and effectiveness. In previous studies, researchers compared Obicetrapib to a placebo to identify any unwanted effects. The results indicated that Obicetrapib was generally well-tolerated, with no significant increase in major side effects compared to the placebo.

One study found that Obicetrapib even helped lower the risk of serious heart problems, suggesting its safety. Another study examined individuals with a type of heart disease and found that Obicetrapib did not cause any major health issues over a year.

Obicetrapib is unique because it targets antioxidant deficiency by potentially enhancing the body's natural ability to manage oxidative stress. Unlike standard treatments that primarily focus on supplementing antioxidants directly, Obicetrapib works by modulating lipid metabolism, which may indirectly boost antioxidant capacity. Researchers are excited about this treatment because it represents a novel approach with the potential to improve cellular resilience against oxidative damage more effectively than conventional antioxidant supplements.

Research has shown that Obicetrapib can significantly increase antioxidant levels in the blood. One study found that it boosts antioxidants like lutein, zeaxanthin, and α-tocopherol within HDL particles, which are part of good cholesterol. Another study suggested that it raises antioxidant levels in both the blood and HDL, while lowering them in non-HDL. This indicates that Obicetrapib might help the body absorb more antioxidants overall. These findings suggest that Obicetrapib could effectively enhance antioxidant levels. Participants in this trial will receive either Obicetrapib or a placebo to further evaluate its effectiveness.¹³⁴⁶⁷